A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis
Moderate Thrombocytopenia
Mild Thrombocytopenia

Interventions

DRUG: Selinexor 60 mg
DRUG: Selinexor 40 mg
DRUG: Ruxolitinib
DRUG: Pacritinib
DRUG: Momelotinib

Sponsor

Karyopharm Therapeutics Inc